1 July 2025 in JCO Precision Oncology
PURPOSE: Germline likely pathogenic and pathogenic variants (LPV/PVs) in POT1 have been associated with an increased risk of various cancers including angiosarcoma, melanoma, glioma, thyroid cancer, and chronic lymphocytic leukemia (CLL). However, to date, most of the published data regarding POT1 PVs involve cohorts of patients selected for specific cancer types, or stem from commercial laboratory cohorts from patients selected for germline clinical testing, which may cause ascertainment biases. The objective was to identify germline POT1 variants in a pan-cancer cohort and describe the associated phenotypes. METHODS: Germline exome data available for 19,315 patients with cancer from the Oncology Research Information Exchange Network (ORIEN) were assessed for POT1 LPV/PV. Data regarding cancer diagnoses were obtained for those with and without POT1 variants. Associations were assessed. RESULTS: POT1 LPV/PVs were identified in 23 patients. The cancer types seen in more than one patient include CLL (n = 7), papillary thyroid cancer (PTC, n = 5), colorectal cancer (n = 3), lung cancer (n = 3), glioblastoma (n = 2), and neuroendocrine tumors (n = 2). Compared with POT1 -negative patients, those with POT1 LPV/PVs were 5.5-fold more likely to be diagnosed with PTC (95% CI, 1.9 to 15.1; P = .004) and 16.6-fold more likely to be diagnosed with CLL (95% CI, 6.4 to 41.9; P < .001). Patients with POT1 LPV/PVs had a younger median age of first cancer diagnosis compared with POT1 -negative patients ( P = .008). CONCLUSION: To our knowledge, this study is the largest investigation of POT1 germline variants in a pan-cancer cohort. We identify and confirm specific associations with CLL and PTC in this cohort. Differences in results between analysis of largely unselected cohorts compared with clinical testing cohorts highlight the need to study gene-cancer associations in more unselected populations.
25 November 2022 in Journal of Genetic Counseling
While genetic testing for hereditary breast and ovarian cancer syndrome (HBOC) is well‐established in the field of medicine, family members' uptake of cascade genetic testing for known familial pathogenic variants remains low. Probands often become responsible for initiating familial communication about their testing results, and barriers to communication may include difficulty in conveying information to relatives and a lack of communication resources for probands' use. In this study, we tested a two‐minute animated digital message (ADM) intervention guided by the Health Belief Model (HBM) in an unselected sample to determine hypothetical individual perceptions of susceptibility and severity and behavioral intention to act on the information provided in the ADM. We recruited genetic testing naïve adults from the United States with no personal history of cancer through Amazon Mechanical Turk to participate in this study. Participants were presented a hypothetical scenario describing a relative's recent HBOC diagnosis, viewed the ADM, and answered a questionnaire assessing participants' perception of the HBM constructs in relation to the hypothetical scenario and participants' intentions to pursue cascade genetic testing, talk to a healthcare professional, or talk to family members after ADM viewing. Participants (n = 373) largely perceived HBOC as serious and believed that they could benefit from the information provided by genetic testing; 76% hypothetically intended to pursue genetic testing at a cost of $100 or less, and 90% intended to either pursue testing or talk to a healthcare provider or family members. This feasibility study in an unaffected population could mimic the experience of distant/less‐engaged relatives in HBOC families after receiving unexpected information about cascade genetic testing. Most participants demonstrated behavioral intention toward cascade testing, at a rate higher than literature would suggest is typical in high‐risk families, indicating that a theory‐supported, simple to use intervention may be useful in clinical practice.
18 June 2025 in Journal of Medical Genetics
Background: Advances in prostate cancer (PCa) research have revealed dozens of genetic markers for inherited risk. Germline genetic testing (GGT) enhances patient care by guiding therapeutic decisions and promoting screening and surveillance for men and their families. We evaluated the impact of embedding a genitourinary (GU) specialised genetic counsellor (GC) into a multidisciplinary GU clinic on counselling referrals, genetic risk assessment and GGT uptake for men with PCa. Methods: A chart review of 2593 individuals with PCa from 2016 to 2022 was performed. Categorical data were analysed by the χ2 test and predictors were identified by logistic regression. Results: Prior to the integration of a GU GC (2016–2018), 39 men were referred for genetic counselling (2%), which increased to 368 men (14%) during 2019–2022. During the pre-embedment period, GGT was completed in 9 out of 39 (23%) referrals, whereas GGT was completed in 235 out of 368 referrals (64%) in the postembedment period. Individuals with a younger age (p<0.0001), family history of PCa (p<0.0001), higher Gleason Score (p<0.0001), more advanced clinical stage (p<0.0001), metastatic disease (p<0.0001), and meeting National Comprehensive Cancer Network guidelines for prostate GGT (p<0.0001) were more likely to be referred. Forty-one tested positive for one or more pathogenic or likely pathogenic variants (17%). Conclusions: The integration of a GC dramatically increased referrals, and a greater proportion of individuals proceeded with GGT. Future studies will analyse barriers and factors promoting referrals so that individuals and their families benefit from evidence-based treatment and early detection and prevention options.
14 December 2022 in Familial Cancer
16 September 2025 in Journal for ImmunoTherapy of Cancer
Background: The heritability of urinary tract cancer (UTC) remains unexplained by known pathogenic germline variants, and the influence of germline variants on treatment response to immune checkpoint inhibition (ICI) has yet to be fully elucidated. Methods: In this case–control study, we performed a germline whole-exome sequencing of 810 UTC patients from the Oncology Research Information Exchange Network. A rare-variant burden test was conducted on the 810 patients and 2354 healthy controls from the Centre d'Etudes du Polymorphisme Humain families, the University of Utah Heritage 1000 Projects, and the 1000 Genomes Project, stratified into discovery and confirmation sets. We used a gene set-based rare-variant association test (GSRVAT) with near-match confirmation, testing for the association of pathways with UTC susceptibility and accounting for multiple testing. We then studied the impact of the identified pathways on tumor biology and clinical course among the 810 cases by analyzing their tumor exomes, transcriptomes, and clinical features. Results: GSRVAT revealed forkhead box p3 (FOXP3) as a susceptibility pathway in 16% of patients with UTC, with an epistasis with DNA mismatch repair. Carriers of germline truncating variants in FOXP3-related susceptibility genes exhibited decreased tumor FOXP3 expression levels, which were associated with a cold tumor microenvironment and significantly reduced overall and progression-free survival following ICI. Conclusions: Germline variants in a set of FOXP3-related genes confer inherent susceptibility to UTC and contribute to resistance against ICI. The immune-evading trait resulting from these variants and the downregulation of FOXP3 expression introduce a novel avenue for personalized medicine through germline and tumor sequencing.
1 October 2025 in JCO Oncology Practice